-
1
-
-
0035008525
-
Ovarian surface epithelium: biology, endocrinology, and pathology
-
&, –
-
Auersperg N., Wong A.S., Choi K.C., Kang S.K. & Leung P.C. (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255–288.
-
(2001)
Endocr. Rev.
, vol.22
, pp. 255-288
-
-
Auersperg, N.1
Wong, A.S.2
Choi, K.C.3
Kang, S.K.4
Leung, P.C.5
-
2
-
-
84859169877
-
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
-
–
-
Barretina J., Caponigro G., Stransky N. et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607.
-
(2012)
Nature
, vol.483
, pp. 603-607
-
-
Barretina, J.1
Caponigro, G.2
Stransky, N.3
-
3
-
-
80052014052
-
Inflammation meets cancer, with NF- κB as the matchmaker
-
&, –
-
Ben-Neriah Y. & Karin M. (2011) Inflammation meets cancer, with NF- κB as the matchmaker. Nat. Immunol. 12, 715–723.
-
(2011)
Nat. Immunol.
, vol.12
, pp. 715-723
-
-
Ben-Neriah, Y.1
Karin, M.2
-
4
-
-
77349099069
-
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
-
–
-
Bignotti E., Todeschini P., Calza S. et al. (2010) Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur. J. Cancer 46, 944–953.
-
(2010)
Eur. J. Cancer
, vol.46
, pp. 944-953
-
-
Bignotti, E.1
Todeschini, P.2
Calza, S.3
-
5
-
-
19744368302
-
Cancer of the ovary
-
–
-
Cannistra S.A. (2004) Cancer of the ovary. N. Engl. J. Med. 351, 2519–2529.
-
(2004)
N. Engl. J. Med.
, vol.351
, pp. 2519-2529
-
-
Cannistra, S.A.1
-
6
-
-
84930199314
-
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
-
–
-
Cardillo TM, Govindan SV, Sharkey RM et al. (2015) Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug. Chem. 26, 919–931.
-
(2015)
Bioconjug. Chem.
, vol.26
, pp. 919-931
-
-
Cardillo, T.M.1
Govindan, S.V.2
Sharkey, R.M.3
-
7
-
-
51649112174
-
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention
-
–
-
Carlson J.W., Miron A., Jarboe E.A. et al. (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 26, 4160–4165.
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 4160-4165
-
-
Carlson, J.W.1
Miron, A.2
Jarboe, E.A.3
-
8
-
-
84875690627
-
Latest research and treatment of advanced-stage epithelial ovarian cancer
-
&, –
-
Coleman R.L., Monk B.J., Sood A.K. & Herzog T.J. (2013) Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 10, 211–224.
-
(2013)
Nat. Rev. Clin. Oncol.
, vol.10
, pp. 211-224
-
-
Coleman, R.L.1
Monk, B.J.2
Sood, A.K.3
Herzog, T.J.4
-
9
-
-
63549123345
-
Intercepting pelvic cancer in the distal fallopian tube: theories and realities
-
–
-
Crum C.P. (2009) Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 3, 165–170.
-
(2009)
Mol Oncol
, vol.3
, pp. 165-170
-
-
Crum, C.P.1
-
10
-
-
70349175559
-
Trop2: a possible therapeutic target for late stage epithelial carcinomas
-
&, –
-
Cubas R., Li M., Chen C. & Yao Q. (2009) Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim. Biophys. Acta 1796, 309–314.
-
(2009)
Biochim. Biophys. Acta
, vol.1796
, pp. 309-314
-
-
Cubas, R.1
Li, M.2
Chen, C.3
Yao, Q.4
-
11
-
-
77956671612
-
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
-
&
-
Cubas R., Zhang S., Li M., Chen C. & Yao Q. (2010) Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol. Cancer. 9, 253.
-
(2010)
Mol. Cancer.
, vol.9
, pp. 253
-
-
Cubas, R.1
Zhang, S.2
Li, M.3
Chen, C.4
Yao, Q.5
-
12
-
-
67649460732
-
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer
-
–
-
Fang Y.J., Lu Z.H., Wang G.Q. et al. (2009) Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int. J. Colorectal Dis. 24, 875–884.
-
(2009)
Int. J. Colorectal Dis.
, vol.24
, pp. 875-884
-
-
Fang, Y.J.1
Lu, Z.H.2
Wang, G.Q.3
-
14
-
-
38649112304
-
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity
-
–
-
Fong D., Spizzo G., Gostner J.M. et al. (2008a) TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod. Pathol. 21, 186–191.
-
(2008)
Mod. Pathol.
, vol.21
, pp. 186-191
-
-
Fong, D.1
Spizzo, G.2
Gostner, J.M.3
-
15
-
-
53849132678
-
High expression of TROP2 correlates with poor prognosis in pancreatic cancer
-
–
-
Fong D., Moser P., Krammel C. et al. (2008b) High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br. J. Cancer 99, 1290–1295.
-
(2008)
Br. J. Cancer
, vol.99
, pp. 1290-1295
-
-
Fong, D.1
Moser, P.2
Krammel, C.3
-
16
-
-
0029146211
-
Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas
-
–
-
Fornaro M., Dell'Arciprete R., Stella M. et al. (1995) Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int. J. Cancer 62, 610–618.
-
(1995)
Int. J. Cancer
, vol.62
, pp. 610-618
-
-
Fornaro, M.1
Dell'Arciprete, R.2
Stella, M.3
-
17
-
-
84941253818
-
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
-
–
-
Goldenberg D.M., Cardillo T.M., Govindan S.V. et al. (2015) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 6, 22496–22512.
-
(2015)
Oncotarget.
, vol.6
, pp. 22496-22512
-
-
Goldenberg, D.M.1
Cardillo, T.M.2
Govindan, S.V.3
-
18
-
-
12144291260
-
Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel
-
–
-
Govindan S.V., Stein R., Qu Z. et al. (2004) Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res. Treat. 84, 173–182.
-
(2004)
Breast Cancer Res. Treat.
, vol.84
, pp. 173-182
-
-
Govindan, S.V.1
Stein, R.2
Qu, Z.3
-
19
-
-
0036107889
-
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology
-
–
-
Iacobuzio-Donahue C.A., Maitra A., Shen-Ong G.L. et al. (2002) Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160, 1239–1249.
-
(2002)
Am. J. Pathol.
, vol.160
, pp. 1239-1249
-
-
Iacobuzio-Donahue, C.A.1
Maitra, A.2
Shen-Ong, G.L.3
-
20
-
-
0028280630
-
Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells
-
–
-
Karlan B.Y., Jones J., Slamon D.J. et al. (1994) Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol. Oncol. 53, 70–77.
-
(1994)
Gynecol. Oncol.
, vol.53
, pp. 70-77
-
-
Karlan, B.Y.1
Jones, J.2
Slamon, D.J.3
-
21
-
-
34547205231
-
Resistance to chemotherapy in ovarian carcinoma: recent results
-
–
-
Lage H., Denkert C. (2007) Resistance to chemotherapy in ovarian carcinoma: recent results. Cancer Res. 176, 51–60.
-
(2007)
Cancer Res.
, vol.176
, pp. 51-60
-
-
Lage, H.1
Denkert, C.2
-
22
-
-
84870953959
-
Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer
-
–
-
Lin H., Huang J.F., Qiu J.R. et al. (2012) Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp. Mol. Pathol. 94, 73–78.
-
(2012)
Exp. Mol. Pathol.
, vol.94
, pp. 73-78
-
-
Lin, H.1
Huang, J.F.2
Qiu, J.R.3
-
23
-
-
0019780296
-
Human trophoblast cell-surface antigens defined by monoclonal antibodies
-
&, –
-
Lipinski M., Parks D.R., Rouse R.V. & Herzenberg L.A. (1981) Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl Acad. Sci. USA 78, 5147–5150.
-
(1981)
Proc. Natl Acad. Sci. USA
, vol.78
, pp. 5147-5150
-
-
Lipinski, M.1
Parks, D.R.2
Rouse, R.V.3
Herzenberg, L.A.4
-
24
-
-
0026808859
-
Simian virus 40- transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix
-
&, –
-
Maines-Bandiera S., Kruk P. & Auersperg N. (1992) Simian virus 40- transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am. J. Obstet. Gynecol. 167, 729–735.
-
(1992)
Am. J. Obstet. Gynecol.
, vol.167
, pp. 729-735
-
-
Maines-Bandiera, S.1
Kruk, P.2
Auersperg, N.3
-
25
-
-
14844346661
-
Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells
-
–
-
Materna V., Liedert B., Thomale J., Lage H. (2005) Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer 115, 393–402.
-
(2005)
Int. J. Cancer
, vol.115
, pp. 393-402
-
-
Materna, V.1
Liedert, B.2
Thomale, J.3
Lage, H.4
-
27
-
-
33744800782
-
Clinical significance of TROP2 expression in colorectal cancer
-
&, –
-
Ohmachi T., Tanaka F., Mimori K., Inoue H., Yanaga K. & Mori M. (2006) Clinical significance of TROP2 expression in colorectal cancer. Clin. Cancer Res. 12, 3057–3063.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 3057-3063
-
-
Ohmachi, T.1
Tanaka, F.2
Mimori, K.3
Inoue, H.4
Yanaga, K.5
Mori, M.6
-
28
-
-
0031800858
-
Human Trop-2 is a tumor-associated calcium signal transducer
-
&, –
-
Ripani E., Sacchetti A., Corda D. & Alberti S. (1998) Human Trop-2 is a tumor-associated calcium signal transducer. Int. J. Cancer 76, 671–676.
-
(1998)
Int. J. Cancer
, vol.76
, pp. 671-676
-
-
Ripani, E.1
Sacchetti, A.2
Corda, D.3
Alberti, S.4
-
29
-
-
80051580618
-
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
-
&, –
-
Siegel R., Ward E., Brawley O. & Jemal A. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212–236.
-
(2011)
CA Cancer J. Clin.
, vol.61
, pp. 212-236
-
-
Siegel, R.1
Ward, E.2
Brawley, O.3
Jemal, A.4
-
30
-
-
84930220109
-
First-in-Human trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the treatment of diverse metastatic solid tumors
-
–
-
Starodub A.N., Ocean A.J., Shah M.A. et al. (2015) First-in-Human trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the treatment of diverse metastatic solid tumors. Clin. Cancer Res. 21, 3870–3878.
-
(2015)
Clin. Cancer Res.
, vol.21
, pp. 3870-3878
-
-
Starodub, A.N.1
Ocean, A.J.2
Shah, M.A.3
-
31
-
-
77955800063
-
(-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells
-
&, –
-
Sukhthankar M., Alberti S. & Baek S.J. (2010) (-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells. Anticancer Res. 30, 2497–2503.
-
(2010)
Anticancer Res.
, vol.30
, pp. 2497-2503
-
-
Sukhthankar, M.1
Alberti, S.2
Baek, S.J.3
-
32
-
-
84921652721
-
Inhibition of microtubule-associated protein1 light chain 3B via small-interfering RNA or 3-methyladenine impairs hypoxia-induced HO8910PM and HO8910 epithelial ovarian cancer cell migration and invasion and is associated with RhoA and alterations of the actin cytoskeleton
-
–
-
Tang Z., Zhang N., Di W. et al. (2015) Inhibition of microtubule-associated protein1 light chain 3B via small-interfering RNA or 3-methyladenine impairs hypoxia-induced HO8910PM and HO8910 epithelial ovarian cancer cell migration and invasion and is associated with RhoA and alterations of the actin cytoskeleton. Oncol. Rep. 33, 1411–1417.
-
(2015)
Oncol. Rep.
, vol.33
, pp. 1411-1417
-
-
Tang, Z.1
Zhang, N.2
Di, W.3
-
33
-
-
79960024794
-
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody
-
–
-
Varughese J., Cocco E., Bellone S. et al. (2011) Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer 117, 3163–3172.
-
(2011)
Cancer
, vol.117
, pp. 3163-3172
-
-
Varughese, J.1
Cocco, E.2
Bellone, S.3
-
34
-
-
33645284166
-
Cetuximab and irinotecan as thirdline therapy in advanced colorectal cancer patients: a single centre phase II trial
-
–
-
Vincenzi B., Santini D., Rabitti C. et al. (2006) Cetuximab and irinotecan as thirdline therapy in advanced colorectal cancer patients: a single centre phase II trial. Br. J. Cancer 94, 792–797.
-
(2006)
Br. J. Cancer
, vol.94
, pp. 792-797
-
-
Vincenzi, B.1
Santini, D.2
Rabitti, C.3
-
35
-
-
39749154101
-
Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
-
&, –
-
Wang J., Day R., Dong Y., Weintraub S.J. & Michel L. (2008) Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol. Cancer Ther. 7, 280–285.
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 280-285
-
-
Wang, J.1
Day, R.2
Dong, Y.3
Weintraub, S.J.4
Michel, L.5
-
36
-
-
84872817120
-
Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma
-
–
-
Wu H., Xu H., Zhang S. et al. (2013) Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck 35, 1373–1378.
-
(2013)
Head Neck
, vol.35
, pp. 1373-1378
-
-
Wu, H.1
Xu, H.2
Zhang, S.3
|